- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07940920
A Personalised Anti-fatigue Program for Community-dwelling People With Chronic Lymphocytic Leukaemia (LIVE-CLL)
Assessment of a Personalised Anti-fatigue Multimodal Program for Community-dwelling People With Chronic Lymphocytic Leukaemia: a Pilot Feasibility Study
The goal of this pilot study is to learn if a personalised, home-based online physical activity program (LIVE-CLL) is feasible for adults with chronic lymphocytic leukaemia (CLL) who experience fatigue. It will also learn if the program improves fatigue, symptoms and quality of life. The main questions it aims to answer are:
Can people with CLL be recruited to the program, attend their prescribed sessions, follow the prescribed exercise intensities, and stay in the study? Do fatigue, symptoms and quality of life change after 12 weeks of the program?
All participants will receive the LIVE-CLL program alongside their usual care. Researchers will compare measurements taken before and after the program.
Participants will:
Complete online fitness assessments and questionnaires by video call before and after the program Follow a personalised 12-week aerobic and strength program at home, 3 to 5 sessions per week, delivered through an exercise app Complete a short check-in form before each session and a wellbeing form each week, so the program can be adjusted
Study Overview
Status
Intervention / Treatment
Detailed Description
Background and rationale
Compared with people with solid tumours, people with haematological malignancies, including CLL, have greater physical deconditioning, worse quality of life and a heavier symptom burden, especially fatigue. In CLL, fatigue is common in treatment-naïve patients, more severe in treated patients, and an independent predictor of poor quality of life. Preliminary survey data collected with the CLL Support Association (approximately 1,000 respondents) show that fatigue prevalence and severity increased between 2022 and 2024, and that patients are rarely referred to services that can address it.
Cancer-related fatigue has many causes. In treated CLL, the BTK inhibitors (e.g., ibrutinib) and BCL2 inhibitors (e.g., venetoclax) have off-target effects on skeletal and cardiac muscle, which may contribute to fatigue and to the higher risk of cardiac events. Fatigue and frailty are also more common in treatment-naïve CLL than in the general population. The investigators' published metabolic biomarker data suggest that CLL cells may use lipid-based fuels that skeletal and cardiac muscle depend on. Together, these mechanisms suggest that fatigue in CLL may differ from fatigue in solid tumours. CLL patients may therefore benefit from a disease-specific, symptom-targeted approach, given at diagnosis (prehabilitation) and when treatment starts (rehabilitation), rather than generic exercise oncology programs.
Patient and public involvement
The intervention design is based on a 2022 patient focus group and online survey of people with CLL. These covered exercise motivations and barriers, intervention preferences, the role of diet and nutrition, and research priorities. It was also refined using feedback from 60 participants who completed a previous 6-month exercise trial run by the investigators. That feedback showed demand for lifestyle approaches that target symptoms such as fatigue and can be delivered in the community.
Study design
This is a prospective, single-arm, pre-test/post-test pilot feasibility study. Formal power calculations were not performed. The target sample of 30 per subgroup (treatment-naïve and on-treatment) follows standard recommendations for pilot studies that aim to generate estimates for powering a definitive trial. Participants are recruited when they are unlikely to change treatment pathway during the study (e.g., moving from watch-and-wait to treatment, or finishing fixed-duration venetoclax). Recruitment is expected to run at 6-10 participants per 4-week period over a 37-week window.
Pre-participation screening
The FACIT-Fatigue is completed online. Eligible participants then have a virtual screening session on MS Teams, which covers medical history, cancer history, emergency contacts and where they will exercise. Exercise readiness is assessed with the PAR-Q+. Participants flagged for further evaluation complete the ePARmed-X+ and need medical clearance from their healthcare provider. Any intensity restrictions the provider recommends are built into the exercise prescription. A Clinical Exercise Physiologist then writes a medical summary form for use during assessments and program delivery.
Remote assessment procedures
Assessments are done by video call with two trained exercise professionals: a primary assessor and a secondary assessor, who records results and supports safety procedures. Before testing, the team checks the participant's home environment and equipment and chooses a suitable test battery. Whether each assessment can be completed remotely is itself a feasibility measure, and not being able to complete a test does not exclude a participant. Physical performance is assessed with standardised online fitness assessment protocols for exercise oncology (Daun et al., 2024). Resting heart rate and blood pressure are measured with the participant's own devices or by assessor-guided pulse palpation. A wrist-worn activity/heart-rate monitor may be posted to participants. Anthropometrics are self-reported using standardised instructions, or taken from a recent clinical record. Patient-reported measures are collected through Qualtrics. Dietary intake is assessed with a 7-day food diary and the short-form food frequency questionnaire. Comorbidity burden is assessed with the CLL Comorbidity Index (CLL-CI).
Intervention
Exercise prescription follows the Sasso et al. (2015) framework for exercise-oncology research and ACSM exercise prescription guidelines, in line with UK Chief Medical Officers' physical activity guidelines. A Clinical Exercise Physiologist writes each program. Programs combine aerobic and resistance exercise to target the limitations found at baseline. Intensity ranges from low (e.g., walking) to moderate (e.g., jogging), based on PAR-Q+ safety zones, and is regulated with ratings of perceived exertion (Borg 6-20 or CR-10). Resistance is adapted to the equipment the participant has, including household items. Programs are delivered through Physitrack, a web and mobile exercise prescription platform used across more than 60 NHS trusts. Participants log in with study-issued IDs, so no personal data is held on the platform. Optional live online group classes are run by a Clinical Exercise Physiologist with a second team member present.
Programs are adjusted continuously based on participant reports. Before each session, participants complete a readiness form covering new injuries, illness and fatigue on a 0-10 scale. If fatigue is above 7/10, or new symptoms are reported, an alternative low-intensity session is offered and the participant is advised to contact the team. A more detailed weekly physical and mental wellbeing form guides progression or regression, and the team arranges a video or phone call if there are wellbeing concerns. An onboarding call introduces the platform before the intervention starts.
Safety monitoring
Self-directed sessions are not monitored in real time. Team support is available 09:00-17:00, Monday to Friday. Out-of-hours risk is managed by:
Giving explicit emergency guidance (call 999; use NHS 111, the GP or the haematology team for urgent non-emergency concerns) Asking participants to tell a contact before each session and keep a phone nearby Encouraging sessions during team hours, especially early in the program Requiring a friend or family member to be present, and team supervision instead of self-directed sessions, for participants classed as weak or frail at baseline
During live sessions, one team member stays with the participant while the second calls emergency services and the emergency contacts.
Exercise-related adverse events are collected from the first exercise test to the last. They are graded with CTCAE v5.0 (or mild to fatal where no CTCAE grading exists) and recorded as related or unrelated to study procedures. Expected minor effects (fatigue, muscle soreness, joint or lower back pain, leg cramps) are not recorded as adverse events. Serious adverse events are reported to the University Ethics Committee within 24 hours. The exercise physiologist is a Level 4 Cancer Rehabilitation Specialist.
Statistical analysis
Participant characteristics will be summarised as mean ± SD or median (IQR), depending on distribution. Feasibility will be judged against pre-set thresholds for recruitment, adherence, compliance and retention. Pre-to-post changes in continuous outcomes will be analysed with linear mixed models, using non-parametric alternatives if data are not normally distributed. Categorical outcomes will be analysed with Pearson chi-square tests. Statistical significance is set at p ≤ 0.05, and trends are noted at p ≤ 0.10. Effect estimates will be used to inform the sample size for a future controlled trial.
Ethics, data management and funding
The study is reviewed by the University of Surrey Ethics Committee. Participants are not recruited through the NHS, so NHS REC review is not required. Data are collected through Qualtrics, moved to secure University servers within 2 weeks, and pseudonymised. Identifiable data are stored separately with restricted access. Records are kept for at least 10 years. The study is funded by Blood Cancer UK.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: David B Bartlett, PhD
- Phone Number: +44
- Email: d.bartlett@surrey.ac.uk
Study Contact Backup
- Name: Ellie Miles, PhD
- Email: e.e.miles@surrey.ac.uk
Study Locations
-
-
-
Guildford, United Kingdom
- Recruiting
- University of Surrey
-
Contact:
- Ellie Miles, PhD
- Email: e.e.miles@surrey.ac.uk
-
Contact:
- David Bartlett, PhD
- Phone Number: +44
- Email: d.bartlett@surrey.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 years or older
- Confirmed diagnosis of chronic lymphocytic leukaemia (CLL), including small lymphocytic lymphoma (SLL), according to International Workshop on CLL (iwCLL) guidelines
- Clinically relevant fatigue, defined as a FACIT-Fatigue total score of less than 34
- Either treatment-naïve or currently receiving CLL treatment, and not expected to change treatment pathway during the 12-week study (e.g., starting treatment or completing fixed-duration therapy)
- Able to provide written informed consent
Exclusion Criteria:
No access to the digital platforms used to assess participants and deliver the program (e.g., internet-connected device for video calls and the exercise app)
- Absolute contraindications to physical activity, including self-reported:
- Acute cardiac event within the past 6 months
- Unstable angina
- Uncontrolled dysrhythmias causing symptoms or haemodynamic compromise
- Symptomatic aortic stenosis
- Uncontrolled symptomatic heart failure
- Acute pulmonary embolus
- Acute myocarditis or pericarditis
- Suspected or known dissecting aneurysm
- Acute systemic infection
- Participants flagged by the PAR-Q+ / ePARmed-X+ as requiring medical clearance, who do not receive clearance to exercise from their healthcare provider
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: LIVE-CLL Program
Adults with CLL and fatigue (FACIT-Fatigue <34), both treatment-naïve and on treatment, receive a personalised 12-week home-based online physical activity program alongside usual care. |
A 12-week, semi-supervised, home-based aerobic and resistance exercise program prescribed by a Clinical Exercise Physiologist using ACSM guidelines. It targets the physical limitations found at baseline assessment. Sessions are 3 to 5 per week, at low to moderate intensity regulated by rating of perceived exertion (Borg scale). They are delivered through the Physitrack app, with optional live online group classes. A readiness check before each session and a weekly wellbeing form are used to progress, regress or replace sessions. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment rate
Time Frame: Over the 37-week recruitment period
|
Number of participants enrolled per 4-week period, and total enrolled against the target of 60. The target rate is 6 to 10 participants per 4 weeks. |
Over the 37-week recruitment period
|
|
Adherence to prescribed sessions
Time Frame: Baseline to week 12
|
Percentage of prescribed weekly exercise sessions completed, recorded on the Physitrack platform. Feasibility is met if adherence is above 85%. |
Baseline to week 12
|
|
Compliance with prescribed exercise intensity and duration
Time Frame: Baseline to week 12
|
Percentage of participants who complete sessions at the prescribed intensity (rating of perceived exertion) and duration, based on session logs. Feasibility is met if more than 80% comply. |
Baseline to week 12
|
|
Retention
Time Frame: Baseline to week 12
|
Percentage of enrolled participants who drop out before the post-intervention assessment. Feasibility is met if fewer than 15% drop out. |
Baseline to week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Completion of remote assessments
Time Frame: Baseline and week 12 (post-intervention)
|
Proportion of planned online physical assessments that are completed successfully. |
Baseline and week 12 (post-intervention)
|
|
FACIT-Fatigue
Time Frame: Baseline and week 12 (post-intervention)
|
Functional Assessment of Chronic Illness Therapy - Fatigue scale. Range 0-52; higher scores mean less fatigue. |
Baseline and week 12 (post-intervention)
|
|
Fatigue Assessment Scale (FAS)
Time Frame: Baseline and week 12 (post-intervention)
|
Range 10-50; higher scores mean more fatigue. |
Baseline and week 12 (post-intervention)
|
|
Fatigue Severity Scale (FSS)
Time Frame: Baseline and week 12 (post-intervention)
|
Mean item score, range 1-7; higher scores mean more severe fatigue. |
Baseline and week 12 (post-intervention)
|
|
Health-related quality of life (EORTC QLQ-C30)
Time Frame: Baseline and week 12 (post-intervention)
|
Global health status, functional scales and symptom scales, each scored 0-100. Higher functional and global scores mean better function. Higher symptom scores mean more symptoms. |
Baseline and week 12 (post-intervention)
|
|
CLL-specific quality of life (EORTC QLQ-CLL17)
Time Frame: Baseline and week 12 (post-intervention)
|
Symptom burden, physical condition/fatigue, and worries/fears scales, each scored 0-100. Higher scores mean more problems. |
Baseline and week 12 (post-intervention)
|
|
Lymphoma-specific quality of life (FACT-Lym)
Time Frame: Baseline and week 12 (post-intervention)
|
Total score 0-168; higher scores mean better quality of life. |
Baseline and week 12 (post-intervention)
|
|
Anxiety and depression (HADS)
Time Frame: Baseline and week 12 (post-intervention)
|
Hospital Anxiety and Depression Scale. Anxiety and depression subscales, each 0-21; higher scores mean more symptoms. |
Baseline and week 12 (post-intervention)
|
|
Cognitive function (FACT-Cog)
Time Frame: Baseline and week 12 (post-intervention)
|
Perceived cognitive impairment and related subscales; higher scores mean better cognitive function. |
Baseline and week 12 (post-intervention)
|
|
Sleep quality (Pittsburgh Sleep Quality Index)
Time Frame: Baseline and week 12 (post-intervention)
|
Global score 0-21; higher scores mean worse sleep quality. |
Baseline and week 12 (post-intervention)
|
|
Geriatric vulnerability (G8)
Time Frame: Baseline and week 12 (post-intervention)
|
Range 0-17; a score of 14 or below indicates geriatric vulnerability. |
Baseline and week 12 (post-intervention)
|
|
Leisure-time physical activity (Godin Leisure-Time Exercise Questionnaire)
Time Frame: Baseline and week 12 (post-intervention)
|
Leisure Score Index; higher scores mean more activity. |
Baseline and week 12 (post-intervention)
|
|
Physical activity level (Stanford Brief Activity Survey)
Time Frame: Baseline and week 12 (post-intervention)
|
Categorical activity level, from inactive to very active. |
Baseline and week 12 (post-intervention)
|
|
Lower-body strength (30-second sit-to-stand test)
Time Frame: Baseline and week 12 (post-intervention)
|
Number of repetitions in 30 seconds. |
Baseline and week 12 (post-intervention)
|
|
Aerobic endurance (2-minute step test)
Time Frame: Baseline and week 12 (post-intervention)
|
Number of steps in 2 minutes. |
Baseline and week 12 (post-intervention)
|
|
Balance (single-leg stance test)
Time Frame: Baseline and week 12 (post-intervention)
|
Time in seconds. |
Baseline and week 12 (post-intervention)
|
|
Lower-body flexibility (chair sit-and-reach test)
Time Frame: Baseline and week 12 (post-intervention)
|
Distance in centimetres. |
Baseline and week 12 (post-intervention)
|
|
Shoulder flexion range of motion
Time Frame: Baseline and week 12 (post-intervention)
|
Degrees |
Baseline and week 12 (post-intervention)
|
|
Resting heart rate and blood pressure
Time Frame: Baseline and week 12 (post-intervention)
|
Beats per minute; mmHg. |
Baseline and week 12 (post-intervention)
|
|
Body mass index
Time Frame: Baseline and week 12 (post-intervention)
|
kg/m², from self-reported height and weight. |
Baseline and week 12 (post-intervention)
|
|
Dietary quality
Time Frame: Baseline and week 12 (post-intervention)
|
Dietary quality score from the short-form food frequency questionnaire (SFFFQ), plus energy and macronutrient intake from a 7-day food diary. |
Baseline and week 12 (post-intervention)
|
|
Exercise-related adverse events
Time Frame: From first exercise test to post-intervention assessment (12 weeks)
|
Number of participants with adverse events related to exercise testing or training, graded with CTCAE v5.0. |
From first exercise test to post-intervention assessment (12 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David Bartlett, PhD, University of Surrey
Publications and helpful links
General Publications
- Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.
- Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for prescription in exercise-oncology research. J Cachexia Sarcopenia Muscle. 2015 Jun;6(2):115-24. doi: 10.1002/jcsm.12042. Epub 2015 May 11.
- Sitlinger A, Deal MA, Garcia E, Connelly M, Thompson D, Stewart T, Macdonald G, Hanson ED, Neely M, Neely B, Artese A, Weinberg JB, Brander D, Bartlett DB. Associations of clinical and circulating metabolic biomarkers with low physical fitness and function in adults with chronic lymphocytic leukemia. Front Oncol. 2022 Aug 3;12:933619. doi: 10.3389/fonc.2022.933619. eCollection 2022.
- Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, Salous T, Hill BT, Alqahtani H, Choi M, Churnetski MC, Cohen JB, Stephens DM, Siddiqi T, Rivera X, Persky D, Wisniewski P, Patel K, Shadman M, Park B, Danilov AV. The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. Clin Cancer Res. 2021 Sep 1;27(17):4814-4824. doi: 10.1158/1078-0432.CCR-20-3993. Epub 2021 Jun 24.
- Eek D, Ivanescu C, Corredoira L, Meyers O, Cella D. Content validity and psychometric evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue scale in patients with chronic lymphocytic leukemia. J Patient Rep Outcomes. 2021 Mar 11;5(1):27. doi: 10.1186/s41687-021-00294-1.
- Shanafelt TD, Bowen D, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Sloan JA, Call TG. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol. 2007 Oct;139(2):255-64. doi: 10.1111/j.1365-2141.2007.06791.x.
- Artese AL, Sitlinger A, MacDonald G, Deal MA, Hanson ED, Pieper CF, Weinberg JB, Brander DM, Bartlett DB. Effects of high-intensity interval training on health-related quality of life in chronic lymphocytic leukemia: A pilot study. J Geriatr Oncol. 2023 Jan;14(1):101373. doi: 10.1016/j.jgo.2022.09.002. Epub 2022 Sep 9.
- MacDonald G, Sitlinger A, Deal MA, Hanson ED, Ferraro S, Pieper CF, Weinberg JB, Brander DM, Bartlett DB. A pilot study of high-intensity interval training in older adults with treatment naive chronic lymphocytic leukemia. Sci Rep. 2021 Nov 30;11(1):23137. doi: 10.1038/s41598-021-02352-6.
- Miles EE, Nicol JL, Fowler H, Roberts A, Hulton AT, Jeary C, Walewska R, Iyengar S, Hanson ED; CLL Support Association; Sitlinger A, Bartlett DB. Physical Activity, Symptoms, Quality of Life and Exercise Program Preferences in People With Chronic Lymphocytic Leukaemia. EJHaem. 2025 Jul 10;6(4):e70100. doi: 10.1002/jha2.70100. eCollection 2025 Aug.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neuroinflammatory Diseases
- Musculoskeletal Diseases
- Nervous System Diseases
- Muscular Diseases
- Pathologic Processes
- Neoplasms by Site
- Neoplasms
- Encephalomyelitis
- Neuromuscular Diseases
- Chronic Disease
- Disease Attributes
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Leukemia, Lymphoid
- Leukemia
- Pathological Conditions, Signs and Symptoms
- Behavior
- Signs and Symptoms
- Hemic and Lymphatic Diseases
- Fatigue Syndrome, Chronic
- Hematologic Neoplasms
- Fatigue
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, B-Cell
- Motor Activity
Other Study ID Numbers
- ERM ID 4435
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Anonymised individual participant data underlying the published results (feasibility metrics, questionnaire scores, physical performance and dietary data) will be shared for participants who consented to data sharing. No directly identifiable information will be shared.
IPD Sharing Time Frame
Data will be available after publication of the primary results and for at least 10 years, in line with the study's data retention policy.
IPD Sharing Access Criteria
Data will be made available to researchers who submit a methodologically sound proposal, on request to the Principal Investigator (d.bartlett@surrey.ac.uk). Access will require a data sharing agreement with the University of Surrey. Data will be shared only for participants who consented to data sharing.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.